Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: Zalcitabine
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

7481-89-2

7481-89-2 structure

7481-89-2 structure

Name: Zalcitabine
Chemical Name: zalcitabine
CAS Number: 7481-89-2
Molecular Formula: C₉H₁₃N₃O₃
Molecular Weight: 211.218
Catalog: Biochemical Nucleoside drugs Deoxynucleotides and their analogues
Create Date: 2018-03-09 08:00:00
Modify Date: 2026-07-02 08:50:49
Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection.

Name	zalcitabine
Synonyms	Zalcitabine - Bio-X 4-Amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one Cytidine, 2',3'-dideoxy 4-Amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydro-2-furanyl]-2(1H)-pyrimidinone Zalcitabine (DISCONTINUED) 2’,3’-Dideoxycytidine, ddC, Zalcitabine 4-Amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-on Zalcitibine 2',3'-Dideoxycytidinene DDC(ZALCITABINE) Human DDC Protein, His Tag dideoxycytidine 2',3'-ddC ddCyd DDC (VAN) ZALCITABINE [2'',3''-DIDEOXYCYTIDINE] 2,3-Dideoxycytidine (ddC) extrapure 2',3'-Dideoxy-D-cytidine 2',3'-Dideoxycytidine/Zalcitabine 3'-Dideoxycytidine D 2C 2,3-DideoxycytidineQ: What is 2,3-Dideoxycytidine Q: What is the CAS Number of 2,3-Dideoxycytidine Q: What is the storage condition of 2,3-Dideoxycytidine Q: What e the applications of 2,3-Dideoxycytidine Dideoxycytidine Cytidine, 2',3'-dideoxy- (8CI, 9CI) 4-Amino-1-(2,3-dideoxy-β-D-ribofuranosyl)pyrimidine-2(1H)-one 2',3'-Didecxycvtidine 4-amino-1-[(2R,5S)-5-(hydroxyméthyl)tétrahydrofuran-2-yl]pyrimidin-2(1H)-one DDC;DIDEOXYCYTIDIN Zalcitabine(2'-3'-dideoxycytidine, ddC) 2', 3'-Dideoxycytidine [3H]-Zalcitabine DDC Dideoxycytidin 2',3'-DIDEOXYCYTIDINE extapure HIVID MFCD00012188 N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]cbamic acid methyl ester Cytidine,2',3'-dideoxy 23Dideoxycytidine, Dideoxycytidine, ddCyd, Hivid ddC 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine Zalcitabine 4-Amino-1-((2R,5S)-5-(hydroxyMethyl)tetrahydrofuran-2-yl)pyriMidin-2(1H)-one 2'',3''-Dideoxycytidine (ddC), nucleoside reverse transcriptase inhibitor (NRTI) 4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]PYRIMIDIN-2-ONE 2'',3''-DIDEOXYCYTIDINE(ZALCITABINE) BETA-D-2',3'-DIDEOXYCYTIDINE 3'-Azido-3'-deoxythymidine ddC (Antiviral) Zalcitabine //BP 2',3'-DIDEOXYCYTIDINE 2’,3’-dideoxy-cytidin I-livid 2',3'-Dideoxycytidine 1-[(2R,5S)-5-(Hydroxymethyl)tetrahydro-2-furanyl]-4-imino-1,4-dihydro-2-pyrimidinol 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 1-(2',3'-DIDEOXY-BETA-RIBOFURANOSYL)CYTOSINE ZALCITABINE 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine 2'', 3''-DIDEOXYCYTIDINE (ZALCITABINE: DDC) Hivid Ro 7/000 Zalcitabine, 10 mM in DMSO 2',3'-Dideoxycytidine (ddC), nucleoside reverse transcriptase inhibitor (NRTI) 2',3'-dideoxy cytidi

Description	Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection.
Related Catalog	Signaling Pathways >> Anti-infection >> HIV Signaling Pathways >> Anti-infection >> Reverse Transcriptase Research Areas >> Infection
Target	Target: HIV
In Vitro	Zalcitabine is a dideoxynucleoside antiretroviral agent that is phosphorylated to the active metabolite 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) within both uninfected and HIV-infected cells. At therapeutic concentrations, ddCTP inhibits HIV replication by inhibiting the enzyme reverse transcriptase and terminating elongation of the proviral DNA chain[1]. Zalcitabine exhibits the inhibition effect on the cellular uptake of [3H]-PAH in CHO/hOAT1 cells with an IC50 value of 1.23 mM. Furthermore, the cellular uptake of zalcitabine increased threefold with the enhancement of hOATI activity in CHO/hOAT1 cells[2].
References	[1]. Adkins JC, et al. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.Drugs. 1997 Jun;53(6):1054-80 [2]. Jin MJ, et al. Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.

Density	1.6±0.1 g/cm3
Boiling Point	415.0±55.0 °C at 760 mmHg
Melting Point	217-218 °C(lit.)
Molecular Formula	C₉H₁₃N₃O₃
Molecular Weight	211.218
Flash Point	204.8±31.5 °C
Exact Mass	211.095688
PSA	90.37000
LogP	-1.30
Vapour Pressure	0.0±2.2 mmHg at 25°C
Index of Refraction	1.686
Storage condition	2-8°C
Stability	Stable. Combustible. Incompatible with strong oxidizing agents.
Water Solubility	5-10 g/100 mL at 19 ºC

CHEMICAL IDENTIFICATION

RTECS NUMBER :: HA3870000

CHEMICAL NAME :: Cytidine, 2',3'-dideoxy-

CAS REGISTRY NUMBER :: 7481-89-2

BEILSTEIN REFERENCE NO. :: 0654956

LAST UPDATED :: 199712

DATA ITEMS CITED :: 9

MOLECULAR FORMULA :: C9-H13-N3-O3

MOLECULAR WEIGHT :: 211.25

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 188 gm/kg/94D-I

TOXIC EFFECTS :: Blood - changes in bone marrow (not otherwise specified) Blood - changes in erythrocyte (RBC) count Blood - changes in leukocyte (WBC) count

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 94 gm/kg/94D-I

TOXIC EFFECTS :: Blood - other changes Blood - changes in other cell count (unspecified) Blood - changes in erythrocyte (RBC) count

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 14500 mg/kg/29D-I

TOXIC EFFECTS :: Blood - other changes Blood - changes in other cell count (unspecified) Blood - changes in erythrocyte (RBC) count

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 91 mg/kg/13W-I

TOXIC EFFECTS :: Tumorigenic - neoplastic by RTECS criteria Endocrine - tumors

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 10 gm/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 20 gm/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

MUTATION DATA

TEST SYSTEM :: Rodent - mouse

DOSE/DURATION :: 600 mg/kg/3D (Continuous)

REFERENCE :: EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 18,168,1991

Symbol	GHS08
Signal Word	Warning
Hazard Statements	H351
Precautionary Statements	P280
Personal Protective Equipment	Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes	Xn:Harmful
Risk Phrases	R40
Safety Phrases	S22-S36
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	HA3870000
HS Code	2934999090

Precursor 7
7481-88-1 119818-52-9 119794-42-2 3768-18-1
125612-00-2 120885-66-7 120885-60-1
DownStream 1
5983-09-5

HS Code	2934999090
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.